Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Compose a Response to This Article
Other responses
No responses have been published for this article.